Sleep

Registry data show worse asthma control, more exacerbations, and higher healthcare utilization in patients with severe asthma and a comorbid sleep disorder.

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

Emerging research highlights the critical link between sleep quality and cardiovascular health.

In this Q&A, Malhotra discusses how tirzepatide impacts obstructive sleep apnea treatment.

Weeks discusses how tirzepatide is impacting treatment strategies for obstructive sleep apnea and driving collaboration across specialties.

CBT-I improved sleep outcomes and achieved 54% remission in patients with chronic pain, cancer, cardiovascular disease, and other chronic conditions.

GLP-1 therapies support weight loss, but OSA requires dedicated airway treatment options such as CPAP or neuromuscular stimulation.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

A recent study from Korea has drawn connections between sleep duration and regularity and major adverse cardiovascular events.

Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.

New data revealed that sleep impairment, especially daytime dysfunction, short duration, and sleep disturbances, is linked to increased diabetes distress.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

Breakthroughs in narcolepsy, idiopathic hypersomnia, OSA, and RLS signal a shift toward personalized care and novel therapies. Check out this June 2025 sleep month in review.

Check out the top 5 interviews from SLEEP 2025.

Sleep Number studies presented at SLEEP 2025 show that heating and cooling patterns improve sleep quality, especially for women experiencing menopause.

At SLEEP 2025, Levine discussed how skin biopsy testing for phosphorylated alpha-synuclein may enable early diagnosis and prevention trials for neurodegenerative diseases.

In this Q&A, Narcisse shared what the association between greater oral microbiome diversity and longer sleep in teens and young adults could mean for early-life disease prevention.

At SLEEP 2025, Sachdeva discussed the evolving legal implications of AI use in sleep medicine, including clinician liability, informed consent, and responsible integration into care.

At SLEEP 2025, HCPLive spoke with Narcisse about NHANES-based findings suggesting longer sleep duration is associated with richer and more diverse oral microbiomes.

At SLEEP 2025, Malhotra emphasized the need for weight loss to resolve obesity hypoventilation syndrome and highlighted limitations of current therapies.

At SLEEP 2025, Malhotra shared updates on diagnosing and managing OHS, including the role of bicarbonate, PAP use, and weight loss.

A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.

At SLEEP 2025, HCPLive spoke to Strollo about the phase 3 SynAIRgy trial which evaluated AD109, a first-in-class, once-daily oral neuromuscular modulator, for OSA.

At SLEEP 2025, Cassiere discussed how pulse oximetry inaccuracies among patients with darker skin tones may lead to underdiagnosis or misclassification of sleep apnea severity.